Hotgen Statement
News Statement
  • 01
  • 02
    Hotgen monkeypox test products help to prevent and control monkeypox
  • Monkeypox is a zoonotic disease caused by monkeypox virus infection, which mainly occurred in Central and West Africa. Since May 2022, monkeypox epidemics have occurred in more than 100 countries and regions around the world. Epidemics in many countries have shown that monkeypox has been transmitted from person to person and has spread widely to countries and regions outside Africa, with a case fatality rate of approximately 0.1%.


    The experience of prevention and control of the COVID-19 epidemic tells us the importance of early detection and early isolation. For an infectious disease that spreads quickly and has a high probability of outbreak, raising awareness of prevention, early identification and effective control are crucial to blocking the epidemic. In May 2022, monkeypox epidemics suddenly broke out in many countries around the world. Hotgen responded quickly and developed both Monkeypox Virus Real-time PCR kit and Monkeypox virus Antigen Rapid Test as soon as possible.


    Monkeypox Virus Real-time PCR kit uses the PCR-fluorescent probe method to detect monkeypox virus-specific target genes with high sensitivity, is compatible with fluorescent PCR platforms, is simple to operate, and can quickly realize the differential diagnosis of monkeypox virus. Monkeypox virus. 

    Monkeypox virus Antigen Rapid Test Kit facilitates rapid diagnosis on-site in 15 minutes, without extra instrument or the tedious solution making and sample extraction.

    Hotgen has been committed to the development of reagents in the field of public safety. Based on the immune and nucleic acid detection platform, it has developed a series of detection products in the field of severe infectious diseases, including Bacillus anthracis, Yersinia pestis, Brucella, and Melioidosis. Kholderia virus, Ebola virus, Zika virus, Dengue virus, Yellow fever virus, West Nile virus, Influenza A virus, Influenza B virus, Respiratory syncytial virus, Francisella tularensis, Pathogen detection products such as Legionella pneumophila and Mycobacterium tuberculosis are widely used in the fields of public safety and disease prevention and control, and have been unanimously recognized by medical and health units such as the Chinese Center for Disease Control and Prevention.

  • 03
    Single-cartridge Chemiluminescence Immunoassay as A Wise Choice to Test HbA1c
  • In a world where diabetes affects millions of people, it is crucial to ensure timely and accurate diagnosis and treatment of the disease, in order to safeguard peoples health and life quality. And single-catridge chemiluminescence HbA1c tests prevail among the diagnostic options.


    On May 19,2023, the World Health Statistics Report 2023 was released on the official website of the World Health Organization (WHO). The report states that diabetes causes 2 million deaths worldwide in 2019 alone. The global adult obesity rate increases rapidly from 8.7% in 2000 to 13.1% in 2016, with the biggest increase occurs in Southeast Asia.

    Diabetes is known as one of the four major killers of human health. And its complications are the most common:
      (1) hypertension, heart disease, and renal arteriosclerosis.
      (2) diabetic bowel disease, such as irregular stool, diarrhea and constipation alternating in 1 or 2 days time.
      (3) repeated difficulty in healing infection, scabies, folliculitis, periodontitis, alveolar thick, pneumonia, urinary tract infection, and etc.
      (4) retinal lesions, complicated by cataract, fundus bleeding, even eventual blindness.
      (5) inflammation of the peripheral nerves. When it gets worse, doctors might resort to amputation to save patients lives.

    Recommended by various medical experts across the globe, HbA1c is an effective detection index for diabetes screening, blood glucose control and efficacy evaluation. Because it can truly and comprehensively reflect the fluctuation of blood glucose of patients, HbA1c Monitoring is the gold standard for determining diabetes treatment efficacy and adjusting treatment options.


    Among the more than 30 clinical methods to test HbA1c, the primarily-adopted methods include immunoassay and HPLC. The HPLC is the standardized method.

    HbA1c test method


    1.Cannot meet the requirements by the European Parliament and the Council in 1998 about the measurement of the clinical laboratory test result.
    2.Expensive instrument.
    3.High maintenance cost & More manual operations.
    4.The variants and hemoglobin derivatives (such as carbamyl hemoglobin, acetyl hemoglobin, HbF, etc.) are easy to interfere with the detection results when co-elution.
    5.Column effect has great influence on the test results.

    Single-catridge CLIA

    1.Principle of antigen-antibody recognition ensures to detect the "true" HbA1c defined by the IFCC reference system.
    2.Excellent anti-interference ability, easy to standardize and repeat.
    3.Higher sensitivity, specificity, recovery rate and accuracy.
    4.Less variation within and between batches,to ensure the accuracy and reliability of clinical test data.
    5.Less cross contamination and less influencing factors.
    6.Individual reagent strip to ensure no cross contamination.
    7.The instrument has no liquid circuit and no maintenance costs.


     In 2013, of the laboratories participated in the American Association of Pathologists (College of American Pathologists, CAP), 67% of the laboratories used CLIA method to test HbA1c, which has become the mainstream method.


    Single-cartridge chemiluminescence method to detect HbA1c eliminates cross contamination with its single reagent strip design. Its instrument has no liquid circuit, and therefore, bears no maintenance cost. It can truly reduce the detection cost and improve the detection efficiency at the same time, to ensure the accuracy and reliability of clinical test data. Single-cartridge chemiluminescence method is a wise choice for HBA1C detection!

  • 04
    Glory Moment | Hotgen Biotech Hornored "China's Top 50 Medical Device Enterprises"
  • On July 3rd, the "15th China Pharmaceutical Industry Development Summit Forum," organized by the China Council for the Promotion of International Trade (CCPIT) Pharmaceutical Industry Chamber of Commerce, was held in Harbin, China. During the event, the highly anticipated "Most Influential Commpanies of the Chinese Pharmaceutical Industry for 2022-2023" list was unveiled. Hotgen Biotech was honored with the title of "Top 50 Medical Device Enterprises in China", and Mr.Changqing Lin, the Chairman of Hotgen Biotech, was honored as one of the "Top Ten Emerging Figures in the Chinese Pharmaceutical Industry".

    Hotgen Biotech's journey of innovation is nothing short of remarkable. Humbly starting from a modest 100-square-meter research laboratory, the company creates distinctive in-vitro diagnostic products that garnered widespread market attention, and quickly expands in the international arena during and after the pandemic era. Their innovative story continues with a comprehensive industry layout covering disease diagnosis and treatment.


    In the field of in-vitro diagnostics, Hotgen Biotech has earned widespread acclaim in the market for its exceptional research and development capabilities and its unique cluster of clinical diagnostic products. Their recent accolade as a "Top 50 Medical Device Enterprise" by this event further underscores Hotgen Biotech's outstanding performance in both technological innovation and market expansion.

    As the helmsman of Hotgen Biotech, Chairman Changqing Lin has consistently advocated the path of "technological innovation" and has led the company to achieve significant accomplishments over the past years. As a contributor to the biopharmaceutical industry, Chairman Changqing Lin has leveraged his rich industry experiences and exceptional leadership to guide Hotgen Biotech in pioneering in the field of biomedicine, contributing to the high-quality development of China's pharmaceutical industry through strategic connections with industry resources.


    In future, Hotgen Biotech will uphold its mission of "development biotechnology for the benefit of human health". They will continue to solidify their distinctive in-vitro diagnostic business through market-oriented innovation. Relying on their core research and development strengths, they will enhance innovative businesses such as antibody drugs, probiotics, and nucleic acid drugs, and deepen their industrial layout from disease diagnosis and treatment to health management, aiming to contribute positively to the rapid development of the biopharmaceutical industry and the realization of "Healthy China" strategic goals.

  • 05
  • 06
About Hotgen
Follow us
About Us